Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20681362 | 0.88 | EGFR (0.54) | EGFRERBB2CTSBCTSCBRPF1 | |
| SCHEMBL21816616 | 0.88 | EGFR (0.59) | EGFR | |
| SCHEMBL20689782 | 0.87 | EGFR (0.52) | EGFRERBB2CTSBCTSCBRPF1 | |
| SCHEMBL23983218 | 0.87 | EGFR (0.53) | EGFRERBB2CTSBCTSCBRPF1 | |
| SCHEMBL20680878 | 0.85 | EGFR (0.51) | EGFRERBB2CTSBCTSCBRPF1 | |
| SCHEMBL23248579 | 0.84 | EGFR (0.64) | EGFR | |
| SCHEMBL25976434 | 0.83 | EGFR (0.50) | EGFRERBB2CTSBCTSCBRPF1 | |
| SCHEMBL23248562 | 0.83 | EGFR (0.49) | EGFRERBB2CTSBCTSCBRPF1 | |
| SCHEMBL23248732 | 0.81 | EGFR (0.51) | EGFR | |
| SCHEMBL25348579 | 0.81 | EGFR (0.46) | EGFRERBB2CTSBCTSCBRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658547-B1 | PROCESS FOR PREPARING N-(5-(4-(4-FORMYL-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YLAMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE | YUHAN CORP (KR) | 2023-08-16 | — | — | EP | claimed |
| US-11198684-B2 | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same | YUHAN CORPORATION (KR) | 2021-12-14 | — | — | US | claimed |
| US-20210155607-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR AGAINST PROTEIN KINASE AND PROCESSES FOR PREPARING THE SAME | YUHAN CORPORATION (KR) | 2021-05-27 | — | — | US | claimed |
| EP-3658547-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR AGAINST PROTEIN KINASE AND PROCESSES FOR PREPARING THE SAME | Yuhan Corporation (KR) | 2020-06-03 | — | — | EP | claimed |
| CN-111032650-A | Novel intermediate useful for synthesis of aminopyrimidine derivative, method for preparing same, and method for preparing aminopyrimidine derivative using same | 株式会社柳韩洋行 | 2020-04-17 | — | — | CN | claimed |
| WO-2019022487-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR AGAINST PROTEIN KINASE AND PROCESSES FOR PREPARING THE SAME | YUHAN CORPORATION (KR) | 2019-01-31 | — | — | WO | claimed |
| EP-3658547-B1 | PROCESS FOR PREPARING N-(5-(4-(4-FORMYL-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YLAMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE | YUHAN CORP (KR) | 2023-08-16 | — | — | EP | disclosed |
| US-11198684-B2 | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same | YUHAN CORPORATION (KR) | 2021-12-14 | — | — | US | disclosed |
| US-20210155607-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR AGAINST PROTEIN KINASE AND PROCESSES FOR PREPARING THE SAME | YUHAN CORPORATION (KR) | 2021-05-27 | — | — | US | disclosed |
| EP-3658547-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR AGAINST PROTEIN KINASE AND PROCESSES FOR PREPARING THE SAME | Yuhan Corporation (KR) | 2020-06-03 | — | — | EP | disclosed |
| CN-111032650-A | Novel intermediate useful for synthesis of aminopyrimidine derivative, method for preparing same, and method for preparing aminopyrimidine derivative using same | 株式会社柳韩洋行 | 2020-04-17 | — | — | CN | disclosed |
| WO-2019022487-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR AGAINST PROTEIN KINASE AND PROCESSES FOR PREPARING THE SAME | YUHAN CORPORATION (KR) | 2019-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155607-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR AGAINST PROTEIN KINASE AND PROCESSES FOR PREPARING THE SAME | ERBB2, EGFR, MAP3K20 | EGFR 2/4885ERBB2 1/4885CTSB 4274/4885 |
| US-11198684-B2 | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same | ERBB2, EGFR, MAP3K20 | EGFR 2/4885ERBB2 1/4885CTSB 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.